Connect with us

BIOTECH

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Is Never Out Of Focus

Published

on

GW Pharmaceuticals PLC- ADR

Latest R&D in the medical cannabis market is assisting industry leaders list breakthroughs and notable discoveries for advancing new patents and treatments for numerous applications aiming diseases including different forms of cancer and rare ailments. Cannabis firms in the markets with developments include one popular name and that is none other than GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH).

The buzz

GW Pharmaceuticals closed down at $97.57.72 on Tuesday. The company reported back in May that that its results from a Phase III trial of Epidiolex® in children with Dravet syndrome were published in The New England Journal of Medicine. Epidiolex, the lead product candidate of GW and the prospective first in a new segment of anti-epileptic medications, is a liquid formulation of plant-derived Cannabidiol, a non-psychoactive CBD, which is being analyzed for the treatment of numerous, grave pediatric-onset epilepsy ailments.

In the study, Epidiolex considerably lowered monthly convulsive seizure frequency versus placebo in highly treatment-resistant kids when added to current treatment. Epidiolex treatment was well taken, with a safety profile consistent with previous open label experience.

Another name in the list is CV Sciences Inc (OTCMKTS:CVSI) that finished Tuesday up slightly at $0.230 by the market close. The firm recently reported that it conducted its pre-IND meeting with the U.S. FDA on June 15, 2017, to assess its drug development plan for ‘CVSI-007’, the firm’s patent-pending offering for smokeless tobacco addiction treatment comprising of nicotine-polacrilex chewing gum together with synthetic Cannabidiol.

Michael J. Mona, Jr., the President and CEO of CV Sciences, expressed that their pre-IND discussions with the FDA was constructive and offered the firm with a favorable advancement roadmap for this vital combination drug candidate.

On Tuesday, another buzzing firm in the same sector, 22nd Century Group Inc (NYSEMKT:XXII) closed down at $1.79. The firm recently reported that, together with The UVA, it has introduced a project aimed at using unique ranges of industrial hemp to clean up and regain abandoned mine lands.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement